Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

EANS-Voting Rights: SYGNIS Pharma AG / Release according to article 26, section 1 WpHG (Securities Trading Act) with the aim of


PR Newswire/euro adhoc/ EANS-Voting Rights: SYGNIS Pharma AG / Release according to article 26, section 1 WpHG (Securities Trading Act) with the aim of Europe-wide distribution Notification of voting rights transmitted by euro adhoc. The issuer is responsible for the content of this announcement.

Announcement according to Article 21, Section 1 of the WpHG (share)

1. BASF SE, Ludwigshafen , Germany has notified us pursuant to section 21 (1) WpHG (German Securities Trading Act) on December 6, 2012, that its percentage of voting rights in SYGNIS Pharma AG fell below the threshold of 3 %, 5% and 10% on December 4, 2012 and amounts to 2.48 % (231,904 voting rights) as per this date.

2. Mr. Prof. Dr. Friedrich von Bohlen und Halbach, Germany, has notified us pursuant to section 21 (1) WpHG on December 7, 2012, that his percentage of voting rights in SYGNIS Pharma AG fell below the threshold of 3 % on December 4, 2012 and amounts to 0.94 % (87,798 voting rights versus to a total amount of 9,349,724 voting rights) as per this date. Of these voting rights, 0.11 % (9,999 voting rights of his children) are to be attributed to him pursuant to section 22 (1) sentence 1 no. 6 WpHG.

3. Mr. Berthold Wipfler, Germany, has notified us pursuant to section 21 (1) WpHG on December 7, 2012, that his percentage of voting rights in SYGNIS Pharma AG fell below the threshold of 50%, 30%, 25%, 20% and 15% on December 4, 2012 and amounts to 12.27 % (1,146,950 voting rights versus to a total amount of 9,349,724 voting rights) as per this date. According to section 22 (1) sentence 1 no. 1 WpHG the voting rights are allocated to Berthold Wipfler. The allocation is due to the companies controlled by Berthold Wipfler with voting rights of each company of 3% or more: BW Verwaltungs GmbH, OH-Capital GmbH & Co. KG, DH-Capital GmbH & Co. KG, OH Beteiligungen GmbH & Co. KG, dievini Hopp BioTech holding GmbH & Co. KG.

4. Mr. Oliver Hopp, Germany, has notified us pursuant to section 21 (1) WpHG on December 7, 2012, that his percentage of voting rights in SYGNIS Pharma AG fell below the threshold of 50%, 30%, 25%, 20% and 15% on December 4, 2012 and amounts to 12.27 % (1,146,950 voting rights versus to a total amount of 9,349,724 voting rights) as per this date. According to section 22 (1) sentence 1 no. 1 WpHG the voting rights are allocated to Oliver Hopp. The allocation is due to the companies controlled by Oliver Hopp with voting rights of each company of 3% or more: BW Verwaltungs GmbH, OH-Capital GmbH & Co. KG, DH-Capital GmbH & Co. KG, OH Beteiligungen GmbH & Co. KG, dievini Hopp BioTech holding GmbH & Co. KG.

5. Mr. Dietmar Hopp, Germany, has notified us pursuant to section 21 (1) WpHG on December 7, 2012, that his percentage of voting rights in SYGNIS Pharma AG fell below the threshold of 50%, 30%, 25%, 20% and 15% on December 4, 2012 and amounts to 12.27 % (1,146,950 voting rights versus to a total amount of 9,349,724 voting rights) as per this date. According to section 22 (1) sentence 1 no. 1 WpHG the voting rights are allocated to Dietmar Hopp. The allocation is due to the companies controlled by Dietmar Hopp with voting rights of each company of 3% or more: BW Verwaltungs GmbH, OH-Capital GmbH & Co. KG, DH-Capital GmbH & Co. KG, OH Beteiligungen GmbH & Co. KG, dievini Hopp BioTech holding GmbH & Co. KG.

6. dievini Hopp BioTech holding GmbH & Co.KG, Walldorf, Germany, has notified us pursuant to section 21 (1) WpHG on December 7, 2012, that its percentage of voting rights in SYGNIS Pharma AG fell below the threshold of 50%, 30%, 25%, 20% and 15% on December 4, 2012 and amounts to 12.27 % (1,146,950 voting rights versus to a total amount of 9,349,724 voting rights) as per this date.

7. DH-Capital GmbH & Co.KG, Wiesloch, Germany, has notified us pursuant to section 21 (1) WpHG on December 7, 2012, that its percentage of voting rights in SYGNIS Pharma AG fell below the threshold of 50%, 30%, 25%, 20% and 15% on December 4, 2012 and amounts to 12.27 % (1,146,950 voting rights versus to a total amount of 9,349,724 voting rights) as per this date. According to section 22 (1) sentence 1 no. 1 WpHG the voting rights are allocated to DH-Capital GmbH & Co.KG. The allocation is due to the companies controlled by DH-Capital GmbH & Co.KG with voting rights of each company of 3% or more: dievini Hopp BioTech holding GmbH & Co. KG.

8. OH Beteiligungen GmbH & Co.KG, Wiesloch, Germany, has notified us pursuant to section 21 (1) WpHG on December 7, 2012, that its percentage of voting rights in SYGNIS Pharma AG fell below the threshold of 50%, 30%, 25%, 20% and 15% on December 4, 2012 and amounts to 12.27 % (1,146,950 voting rights versus to a total amount of 9,349,724 voting rights) as per this date. According to section 22 (1) sentence 1 no. 1 WpHG the voting rights are allocated to OH Beteiligungen GmbH & Co.KG. The allocation is due to the companies controlled by OH Beteiligungen GmbH & Co.KG with voting rights of each company of 3% or more: dievini Hopp BioTech holding GmbH & Co. KG.

9. OH-Capital GmbH & Co.KG, Wiesloch, Germany, has notified us pursuant to section 21 (1) WpHG on December 7, 2012, that its percentage of voting rights in SYGNIS Pharma AG fell below the threshold of 50%, 30%, 25%, 20% and 15% on December 4, 2012 and amounts to 12.27 % (1,146,950 voting rights versus to a total amount of 9,349,724 voting rights) as per this date. According to section 22 (1) sentence 1 no. 1 WpHG the voting rights are allocated to OH-Capital GmbH & Co.KG. The allocation is due to the companies controlled by OH-Capital GmbH & Co.KG with voting rights of each company of 3% or more: dievini Hopp BioTech holding GmbH & Co. KG, OH Beteiligungen GmbH & Co. KG.

10. BW Verwaltungs GmbH, Wiesloch, Germany, has notified us pursuant to section 21 (1) WpHG on December 7, 2012, that its percentage of voting rights in SYGNIS Pharma AG fell below the threshold of 50%, 30%, 25%, 20% and 15% on December 4, 2012 and amounts to 12.27 % (1,146,950 voting rights versus to a total amount of 9,349,724 voting rights) as per this date. According to section 22 (1) sentence 1 no. 1 WpHG the voting rights are allocated to BW Verwaltungs GmbH. The allocation is due to the companies controlled by BW Verwaltungs GmbH with voting rights of each company of 3% or more: dievini Hopp BioTech holding GmbH & Co. KG, OH Beteiligungen GmbH & Co. KG, DH-Capital GmbH & Co. KG, OH-Capital GmbH & Co. KG.

11. DH-Holding GmbH & Co. KG, Wiesloch, Germany, has notified us pursuant to section 21 (1) WpHG on December 7, 2012, that its percentage of voting rights in SYGNIS Pharma AG fell below the threshold of 50%, 30%, 25%, 20% and 15% on December 4, 2012 and amounts to 12.27 % (1,146,950 voting rights versus to a total amount of 9,349,724 voting rights) as per this date. According to section 22 (1) sentence 1 no. 1 WpHG the voting rights are allocated to DH-Holding GmbH & Co. KG. The allocation is due to the companies controlled by DH-Holding GmbH & Co. KG with voting rights of each company of 3% or more: dievini Hopp BioTech holding GmbH & Co. KG,, DH-Capital GmbH & Co. KG.

12. DH-Holding Verwaltungs GmbH, Wiesloch, Germany, has notified us pursuant to section 21 (1) WpHG on December 7, 2012, that its percentage of voting rights in SYGNIS Pharma AG fell below the threshold of 50%, 30%, 25%, 20% and 15% on December 4, 2012 and amounts to 12.27 % (1,146,950 voting rights versus to a total amount of 9,349,724 voting rights) as per this date. According to section 22 (1) sentence 1 no. 1 WpHG the voting rights are allocated to DH-Holding Verwaltungs GmbH. The allocation is due to the companies controlled by DH-Holding Verwaltungs GmbH with voting rights of each company of 3% or more: dievini Hopp BioTech holding GmbH & Co. KG, DH-Capital GmbH & Co. KG, DH-Holding GmbH & Co. KG.

Further inquiry note: Marc Risch Telefon: +49 (6221) 454 - 737 E-Mail: Marc.Risch@sygnis.de

issuer: SYGNIS Pharma AG

Im Neuenheimer Feld 515

D-69120 Heidelberg phone: +49 (0)6221 454-6 FAX: +49 (0)6221 454-777 mail: contact@sygnis.de WWW: http://www.sygnis.de sector: Biotechnology ISIN: DE000A1RFM03 indexes: stockmarkets: language: English

The content and accuracy of news releases published on this site and/or distributed by PR Newswire or its partners are the sole responsibility of the originating company or organisation. Whilst every effort is made to ensure the accuracy of our services, such releases are not actively monitored or reviewed by PR Newswire or its partners and under no circumstances shall PR Newswire or its partners be liable for any loss or damage resulting from the use of such information. All information should be checked prior to publication.

-0- Dec/07/2012 17:41 GMT

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement